Posters/Publications

poster

FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer

San Antonio Breast Cancer Symposium

poster

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

ObesityWeek

poster

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

AASLD

poster

Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone

Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

poster

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

Keystone Symposium on Organ Crosstalk in Obesity and NAFLD

poster

Fatty acid synthase inhibitor TVB-3664 reverses multiple components of diet-induced nonalcoholic steatohepatitis in mice treated with or without co-administered pirfenidone and reduces collagen accumulation in bleomycin-induced murine skin fibrosis

AASLD

poster

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

AASLD

oral

First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

AACR Annual Meeting

poster

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH

EASL International Liver Congress

paper

Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

Pharmacology and Therapeutics

Scroll to Top